| Medical and Health Sciences | 2021-2025 | 814 | PL 5 | 99.81 |
| Medical Genetics | Lifetime | 73 | PL 1 | 99.44 |
| Pathology and Forensic Medicine | Lifetime | 231 | PL 1 | 99.15 |
| Hematology | Lifetime | 229 | PL 2 | 98.71 |
| Immunology | Lifetime | 786 | PL 3 | 97.46 |
| Rheumatology | Lifetime | 948 | PL 3 | 94.37 |
| Medical Genetics | 2021-2025 | 21 | PL 1 | 99.48 |
| Pathology and Forensic Medicine | 2021-2025 | 106 | PL 1 | 97.58 |
| Hematology | 2021-2025 | 146 | PL 3 | 95.92 |
| Immunology | 2021-2025 | 750 | PL 5 | 75.61 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 82 | PL 1 | 99.47 |
| Lymphoma Diagnosis and Treatment | Lifetime | 127 | PL 1 | 99.57 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 124 | PL 1 | 99.60 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 136 | PL 1 | 99.20 |
| Acute Lymphoblastic Leukemia research | Lifetime | 210 | PL 1 | 99.13 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 646 | PL 1 | 98.93 |
| Multiple Myeloma Research and Treatments | Lifetime | 220 | PL 1 | 98.58 |
| Acute Myeloid Leukemia Research | Lifetime | 433 | PL 1 | 98.81 |
| Advanced Breast Cancer Therapies | Lifetime | 170 | PL 2 | 98.54 |
| Viral-associated cancers and disorders | Lifetime | 320 | PL 1 | 98.16 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 277 | PL 1 | 97.27 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 362 | PL 4 | 96.55 |
| Biochemical and Molecular Research | Lifetime | 886 | PL 6 | 95.43 |
| Blood groups and transfusion | Lifetime | 860 | PL 4 | 95.53 |
| Platelet Disorders and Treatments | Lifetime | 876 | PL 3 | 96.08 |
| Angiogenesis and VEGF in Cancer | Lifetime | 894 | PL 3 | 95.33 |
| Histone Deacetylase Inhibitors Research | Lifetime | 791 | PL 4 | 93.69 |
| Eosinophilic Disorders and Syndromes | Lifetime | 850 | PL 2 | 94.55 |
| Protein Degradation and Inhibitors | Lifetime | 954 | PL 4 | 94.06 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 968 | PL 1 | 93.83 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 34 | PL 2 | 99.46 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 40 | PL 2 | 99.43 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 35 | PL 1 | 98.78 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 63 | PL 2 | 98.68 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 379 | PL 3 | 90.86 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 585 | PL 8 | 91.72 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 613 | PL 7 | 92.03 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 230 | PL 8 | 90.40 |
| Advanced Breast Cancer Therapies | 2021-2025 | 715 | PL 5 | 87.06 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 289 | PL 3 | 85.85 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 623 | PL 3 | 66.87 |
